Lisa Abdishoo
Internal Medicine · Tustin, CANPI 1881776326
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 36.0% of the total. Reporting peaked in 2023 at $258 and has fallen 62.1% since, to $98 in 2025.
Across 7 payments — averaging $54.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$137
- Otsuka America Pharmaceutical, Inc.$121
- AbbVie$55
- Indivior Inc.$30
- Exact Sciences$20
- Braeburn Inc.$18
Across 2 payments — averaging $248,039 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Diagnostics Operations, Inc.$496K
What the payments were for
- Food & beverage$381100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 1 | $137 |
| Otsuka America Pharmaceutical, Inc. | 1 | $121 |
| AbbVie | 2 | $55 |
| Indivior Inc. | 1 | $30 |
| Exact Sciences | 1 | $20 |
| Braeburn Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$137
- ABILIFY MAINTENA$121
How this compares
$381 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 21 | $24,716 |
| OzempicSemaglutide | 23 | $24,470 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $1,614 |
| Atorvastatin Calcium | 82 | $527 |
| Gabapentin | 37 | $376 |
| Metformin Hcl | 34 | $229 |
| Tamsulosin Hcl | 25 | $224 |
| Fluticasone Propionate | 19 | $209 |
| Lisinopril | 37 | $206 |
| Hydroxyzine Hcl | 14 | $199 |
| Diclofenac Sodium | 22 | $191 |
| Losartan Potassium | 21 | $187 |
| Levothyroxine Sodium | 13 | $174 |
| Amlodipine Besylate | 60 | $131 |
| Naproxen | 16 | $113 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Tustin
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.